Clinical Trial: Predictive Value of ctDNA Methylation Combined with Multi-subtype Circulating Tumor Cell Detection for Recurrence Risk after Neoadjuvant Therapy in Non-small Cell Lung Cancer (China)

Posted On: 2026-10-01

China, Oct. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Predictive Value of ctDNA Methylation Combined with Multi-subtype Circulating Tumor Cell Detection for Recurrence Risk after Neoadjuvant Therapy in Non-small Cell Lung Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133715

Registration Time: 2026/09/30

Type: Observational study

Primary Sponsor: Huadong Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345945

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Predictive Value of ctDNA Methylation Combined with Multi-subtype Circulating Tumor Cell Detection for Recurrence Risk after Neoadjuvant Therapy in Non-small Cell Lung Cancer (China)